TrovaGene Inc (NASDAQ:TROV) fell 6.3% during mid-day trading on Thursday . The company traded as low as $0.29 and last traded at $0.30. 747,131 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 1,541,592 shares. The stock had previously closed at $0.32.
A number of brokerages have recently issued reports on TROV. Maxim Group set a $4.00 target price on shares of TrovaGene and gave the company a “buy” rating in a research report on Wednesday, October 18th. HC Wainwright began coverage on shares of TrovaGene in a research report on Thursday, December 21st. They issued a “buy” rating and a $1.00 target price for the company. Finally, cut shares of TrovaGene from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $3.70.
The company has a market capitalization of $15.95, a PE ratio of -0.30 and a beta of 0.40.
An institutional investor recently raised its position in TrovaGene stock. Susquehanna International Group LLP grew its holdings in TrovaGene Inc (NASDAQ:TROV) by 254.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 488,937 shares of the medical research company’s stock after acquiring an additional 350,906 shares during the quarter. Susquehanna International Group LLP owned 1.28% of TrovaGene worth $357,000 as of its most recent SEC filing. Institutional investors own 9.91% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “TrovaGene (TROV) Shares Down 6.3%” was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3147381/trovagene-trov-shares-down-6-3.html.
TrovaGene Company Profile
Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.
Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with MarketBeat.com's FREE daily email newsletter.